Eisai starts phase 3 trials for second Alzheimer’s drug after first’s failure

March 22, 2019 admin Business News Comments Off on Eisai starts phase 3 trials for second Alzheimer’s drug after first’s failure

Eisai Co Ltd on Friday said it has begun phase 3 clinical trials of Alzheimer’s treatment BAN2401, a day after the Japanese drugmaker and U.S. partner Biogen Inc scrapped trials for another Alzheimer’s drug, aducanumab.

…read more

Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential!
Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of the crowd.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.

Source:: Reuters – Business News